Search - tctmd.com

Displaying 1 - 20 of 30

Sort: Relevancy | Date

Presentation TCT 2025

TCT 68: Early Initiation of PCSK9 Inhibitors in Acute STEMI: Safety and Efficacy Outcomes from the EARLY-STEMI Trial

Presenter: Mohammed Ali

October 28, 2025

Presentation TCT 2025

TCT 1004: Cardiovascular Outcomes of PCSK9 Inhibitor Use in Percutaneous Coronary Intervention

Presenter: Grant William Reed

October 27, 2025

Presentation TCT 2025

TCT 1261: Effect of PCSK9 Inhibitors on Coronary Plaque: A Meta-Analysis and Trial Sequential Analysis

Presenter: Paulo Roberto Tartuce Filho

October 27, 2025

Presentation TCT India 2025

Newer Lipid therapy Guidelines – Role of PCSK9 Inhibitors in ACS

Presenter: M. Srinivasa Rao

July 26, 2025

Presentation TCT 2024

Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease

Presenter: Jonathan Los

October 27, 2024

Presentation TCT 2023

STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors

Presenter: Sanjit Jolly

October 25, 2023

Presentation ACC 2023

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Presenter: Christie Ballantyne

March 05, 2023

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Presentation Cardiovascular Interventions 2019

PCSK9 Inhibitors for the Interventionalist: Which Patients Do We Choose and How Do We Use?

Presenter: Matthew J. Budoff

November 01, 2019

Presentation TCT 2019

Role of PCSK9 Inhibitors Post-PCI and ACS

Presenter: Marc Bonaca

September 26, 2019

Presentation Controversies and Advances 2017

PCSK9 Inhibitors - Are They Worth The Money?

Presenter: Michael J. Blaha

November 16, 2017

Presentation TCT 2017

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

Presenter: Gregg W. Stone, Peter H. Stone, Evan A. Stein

November 01, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

Presentation TCT 2016

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Presenter: Gregg W. Stone, Ron Waksman, Sanjit S. Jolly

November 01, 2016

Presentation TCT 2016

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Presenter: Bernard J. Gersh, Felix Mahfoud, Ori Ben-Yehuda

November 01, 2016

Presentation TCT 2016

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Presenter: Bernard J. Gersh, Felix Mahfoud, Evan A. Stein

November 01, 2016

Presentation TCT 2016

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Presenter: Bernard J. Gersh, Felix Mahfoud

November 01, 2016

Presentation TCT 2015

Statin Pretreatment Prior to PCI: Are the Effects Real?

Presenter: Frederick Feit, C. Michael Gibson, Germano Di Sciascio

October 15, 2015

Presentation TCT 2015

Cilostazol: When to Consider (and Is the Data Robust?)

Presenter: Frederick Feit, C. Michael Gibson

October 15, 2015

Presentation TCT 2015

The PCSK9 Inhibitor Revolution

Presenter: Frederick Feit, C. Michael Gibson, Norman E. Lepor

October 15, 2015

Advertisement

TCT 68: Early Initiation of PCSK9 Inhibitors in Acute STEMI: Safety and Efficacy Outcomes from the EARLY-STEMI Trial

TCT 1004: Cardiovascular Outcomes of PCSK9 Inhibitor Use in Percutaneous Coronary Intervention

TCT 1261: Effect of PCSK9 Inhibitors on Coronary Plaque: A Meta-Analysis and Trial Sequential Analysis

Newer Lipid therapy Guidelines – Role of PCSK9 Inhibitors in ACS

Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease

STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

PCSK9 Inhibitors for the Interventionalist: Which Patients Do We Choose and How Do We Use?

Role of PCSK9 Inhibitors Post-PCI and ACS

PCSK9 Inhibitors - Are They Worth The Money?

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Statin Pretreatment Prior to PCI: Are the Effects Real?

Cilostazol: When to Consider (and Is the Data Robust?)

The PCSK9 Inhibitor Revolution

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content